Last update 13 Dec 2025

MK-1966

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
MK 1966
Target
IL-10
Action
inhibitors
Mechanism
IL-10 inhibitors(Interleukin-10 inhibitors)
Therapeutic Areas
NeoplasmsHemic and Lymphatic Diseases
Active Indication
Hematologic Neoplasms
Inactive Indication
Advanced cancer
Originator Organization
Merck Sharp & Dohme Corp.Merck Sharp & Dohme Corp.
Active Organization
Dynavax Technologies Corp.Dynavax Technologies Corp.Merck Sharp & Dohme Corp.Merck Sharp & Dohme Corp.
Inactive Organization
Merck GmbH
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with MK-1966
NCT02731742
/ TerminatedPhase 1
A Phase 1/1b Trial of MK-1966 in Combination With SD-101 in Subjects With Advanced Malignancies
100 Clinical Results associated with MK-1966
Login to view more data
100 Translational Medicine associated with MK-1966
Login to view more data
100 Patents (Medical) associated with MK-1966
Login to view more data
100 Deals associated with MK-1966
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced cancerPhase 1-
Merck Sharp & Dohme Corp.Merck Sharp & Dohme Corp.
22 Jun 2016
Hematologic NeoplasmsPhase 1
United States
Merck GmbH
-
Hematologic NeoplasmsPhase 1-
Dynavax Technologies Corp.Dynavax Technologies Corp.
-
Hematologic NeoplasmsPhase 1-
Merck Sharp & Dohme Corp.Merck Sharp & Dohme Corp.
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT02731742 (1966-001 | MK-1966-001, CTgov)
Phase 1
Advanced cancer
14
(MK-1966 70 mg+SD-101 1 mg)
vtulizxhio = eshqxozgsf euyzfjltxz (gsisartycs, tbgnlpuzfp - bxaixoaars)
View more
-
04 Feb 2019
(MK-1966 70 mg+SD-101 4 mg)
vtulizxhio = zwgfqyjamw euyzfjltxz (gsisartycs, ofmnctecjf - unqyxyqebm)
View more
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free